Total Payments
$27,717
2024 Payments
$98.95
Companies
30
Transactions
131
Medicare Patients
1,618
Medicare Billing
$134,990
Payment Breakdown by Category
Other$13,160 (47.5%)
Consulting$8,710 (31.4%)
Food & Beverage$3,361 (12.1%)
Travel$2,007 (7.2%)
Education$478.74 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,160 | 8 | 36.7% |
| Consulting Fee | $8,710 | 6 | 31.4% |
| Food and Beverage | $3,361 | 92 | 12.1% |
| Honoraria | $3,000 | 4 | 10.8% |
| Travel and Lodging | $2,007 | 11 | 7.2% |
| Education | $478.74 | 10 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $9,003 | 30 | $0 (2019) |
| Cardinal Health 414, LLC | $5,270 | 12 | $0 (2017) |
| Athenex Pharmaceutical Division, LLC | $2,800 | 3 | $0 (2020) |
| PFIZER INC. | $2,445 | 4 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $2,426 | 5 | $0 (2022) |
| Exelixis Inc. | $2,297 | 7 | $0 (2019) |
| Incyte Corporation | $843.04 | 5 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $382.28 | 6 | $0 (2022) |
| Genentech USA, Inc. | $287.85 | 12 | $0 (2022) |
| Daiichi Sankyo Inc. | $250.59 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98.95 | 1 | Genmab U.S., Inc. ($98.95) |
| 2023 | $200.00 | 1 | Daiichi Sankyo Inc. ($200.00) |
| 2022 | $1,102 | 30 | E.R. Squibb & Sons, L.L.C. ($256.26) |
| 2021 | $248.92 | 13 | TG THERAPEUTICS, INC. ($124.99) |
| 2020 | $2,847 | 6 | Athenex Pharmaceutical Division, LLC ($2,800) |
| 2019 | $2,828 | 9 | Amgen Inc. ($2,552) |
| 2018 | $7,633 | 17 | PFIZER INC. ($2,400) |
| 2017 | $12,758 | 54 | Cardinal Health 414, LLC ($5,270) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $98.95 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Daiichi Sankyo Inc. | — | Honoraria | Cash or cash equivalent | $200.00 | General |
| 12/13/2022 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Oncology | ||||||
| 12/06/2022 | Genentech USA, Inc. | GAZYVA (Biological), VENCLEXTA, POLIVY | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: BioOncology | ||||||
| 12/02/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Oncology | ||||||
| 12/01/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Oncology | ||||||
| 11/22/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $11.32 | General |
| Category: Oncology | ||||||
| 11/16/2022 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $120.69 | General |
| Category: Oncology | ||||||
| 11/02/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $8.37 | General |
| Category: Oncology | ||||||
| 11/01/2022 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: BioOncology | ||||||
| 10/27/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Oncology | ||||||
| 10/21/2022 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $73.52 | General |
| Category: Oncology | ||||||
| 10/19/2022 | Kyowa Kirin, Inc. | POTELIGEO (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Monoclonal Antibody | ||||||
| 10/18/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Oncology | ||||||
| 10/17/2022 | Seagen Inc. | — | Education | In-kind items and services | $85.95 | General |
| 10/10/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $61.99 | General |
| 10/06/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Oncology | ||||||
| 09/28/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Oncology | ||||||
| 09/01/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX, PAXLOVID | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ONCOLOGY | ||||||
| 08/24/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONC | ||||||
| 07/28/2022 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: ONCOLOGY | ||||||
| 07/21/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| Category: Oncology | ||||||
| 06/30/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, PAXLOVID | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 77 | 89 | $40,510 | $5,029 |
| 2022 | 10 | 546 | 1,281 | $220,282 | $50,368 |
| 2021 | 9 | 547 | 1,245 | $183,075 | $48,908 |
| 2020 | 9 | 448 | 717 | $122,570 | $30,685 |
Total Patients
1,618
Total Services
3,332
Medicare Billing
$134,990
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 33 | 39 | $18,447 | $2,112 | 11.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $12,319 | $1,745 | 14.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 29 | $9,744 | $1,172 | 12.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 239 | $87,344 | $20,266 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 52 | $25,560 | $6,743 | 26.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 66 | $21,989 | $5,046 | 22.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 30 | $19,168 | $4,432 | 23.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 68 | $18,647 | $3,868 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $18,407 | $3,817 | 20.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 123 | 351 | $14,004 | $2,650 | 18.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 38 | $8,865 | $2,018 | 22.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 127 | 380 | $4,466 | $1,128 | 25.3% |
| 36591 | Collection of blood sample from implanted device | Office | 2022 | 13 | 22 | $1,833 | $400.59 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 105 | 224 | $68,412 | $18,972 | 27.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 63 | $26,048 | $8,209 | 31.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 62 | 94 | $19,046 | $5,689 | 29.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 34 | 37 | $22,550 | $5,508 | 24.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 33 | 33 | $15,477 | $3,547 | 22.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 127 | 364 | $14,462 | $2,809 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 35 | $11,316 | $2,736 | 24.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 122 | 374 | $4,237 | $1,114 | 26.3% |
| 36591 | Collection of blood specimen from a completely implantable venous access device | Office | 2021 | 13 | 21 | $1,527 | $325.61 | 21.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 90 | 142 | $42,184 | $10,907 | 25.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 108 | $26,892 | $6,447 | 24.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 23 | 23 | $10,697 | $2,743 | 25.6% |
About Dr. Wei Lin, MD
Dr. Wei Lin, MD is a Internal Medicine healthcare provider based in Cloquet, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386621654.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wei Lin, MD has received a total of $27,717 in payments from pharmaceutical and medical device companies, with $98.95 received in 2024. These payments were reported across 131 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,160).
As a Medicare-enrolled provider, Lin has provided services to 1,618 Medicare beneficiaries, totaling 3,332 services with total Medicare billing of $134,990. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Internal Medicine
- Location Cloquet, MN
- Active Since 12/28/2005
- Last Updated 03/20/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1386621654
Products in Payments
- XGEVA (Biological) $6,621
- Oral Paclitaxel (Drug) $2,800
- MYLOTARG (Biological) $2,413
- IMFINZI (Drug) $2,350
- Cabometyx (Drug) $2,297
- Prolia (Biological) $1,800
- Nplate (Biological) $317.14
- OPDIVO (Biological) $274.42
- Erleada (Drug) $231.00
- Revlimid (Drug) $156.16
- Lenvima (Drug) $152.86
- TIBSOVO (Drug) $128.99
- UKONIQ (Drug) $124.99
- NINLARO (Drug) $118.31
- SOLIRIS (Drug) $113.12
- Neulasta (Biological) $108.87
- ROZLYTREK (Biological) $102.03
- Epkinly (Drug) $98.95
- JAKAFI (Drug) $98.10
- EMPLICITI (Biological) $97.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.